Sun Yat-sen University: Neoplasm Metastasis trials

The registry lists 44 Neoplasm Metastasis studies with Sun Yat-sen University as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 21Phase 3 9Phase 4 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal CarcinomaNot yet recruitingNCT07824856Phase 2
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Phase 1
• Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerNot yet recruitingNCT07405736Phase 2
• Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRIRecruitingNCT06831357
• A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)RecruitingNCT06829147
• Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast CancerNot yet recruitingNCT06383663Not applicable
• Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNCT06265350Not applicable
• Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal CancerRecruitingNCT05933980Phase 2
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver MetastasesRecruitingNCT05794971Phase 3
• Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesRecruitingNCT05768490Phase 3
• Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
• Preoperative Systemic Therapy for Colorectal Cancer Peritoneal MetastasesNot yet recruitingNCT05353582Phase 2
• A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRCRecruitingNCT03303495Phase 3
• The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate CancerCompletedNCT06915714
• Osteosclerotic Changes on CT Predict Survival in Prostate CancerCompletedNCT06883474
• Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesCompletedNCT05807893Phase 2/3
• Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR MutationStatus unknownNCT05616377
• Treatments for Brain Metastases With Poor Prognostic FactorsStatus unknownNCT05609162
• Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLMStatus unknownNCT05485909Phase 2
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
• Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
• Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cmStatus unknownNCT04686942
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
• Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
• Systemic Chemotherapy Plus PD-1 for Metastasis ICCWithdrawnNCT04398927Phase 2
• GM1 Prophylaxis for WBRT Related Cognitive DysfunctionTerminatedNCT04395339Phase 3
• Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCCompletedNCT04345146Phase 2
• Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
• The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal CancerStatus unknownNCT04230018
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
• FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLMTerminatedNCT03678428Phase 3
• Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLMTerminatedNCT03500874Phase 3
• A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLMCompletedNCT03493061Phase 2
• A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain MetastasesStatus unknownNCT03257735
• Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)Status unknownNCT03129854Not applicable
• A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain MetastasesStatus unknownNCT02832635Phase 2
• EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCStatus unknownNCT02714010Phase 3
• Maintenance Treatment With Capecitabine in Colorectal Cancer PatientsStatus unknownNCT02027363Phase 2
• Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Phase 2
• Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01951469Phase 3
• Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving BisphosphonatesCompletedNCT00765687Phase 4
• Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone MetastasisCompletedNCT00762346Phase 4